• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Kyowa Hakko Kirin joins Certara’s Simcyp consortium

Kyowa Hakko Kirin joins Certara’s Simcyp consortium

September 13, 2017
CenterWatch Staff

Certara, a provider of model-informed drug development and regulatory science, announced that Kyowa Hakko Kirin has joined the Simcyp Consortium and licensed the Simcyp Population-based Simulator. Kyowa Hakko Kirin is the 36th leading biopharmaceutical company and the 11th Japanese pharmaceutical company to join the Consortium. Member companies meet in a pre-competitive environment and work together to progress the evolution of modeling and simulation (M&S) and the Simcyp Simulator.

“We are thrilled to have Kyowa Hakko Kirin as a member of the Simcyp Consortium,” said Stephen Toon, BPharm, Ph.D., President and Managing Director of Certara’s Simcyp division. “Membership provides numerous benefits, including the opportunity to share knowledge and collaborate in the development of best practices and cutting-edge science for studying drug activity in virtual patients. In addition to creating annual updates to the Simcyp Simulator, Simcyp has also produced models for pediatric, pregnant, obese, hepatic- and renally-impaired populations. These advances have enabled member companies to evaluate new therapies in patient groups and clinical scenarios that might have historically been considered ‘untestable.’”

Underscoring that fact that M&S has progressed from a scientific nicety to a regulatory necessity, leading academic institutions and key regulatory bodies from around the world, including the FDA, EMA, and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) are affiliates of the Simcyp Consortium.

In the US, the Simcyp Simulator has informed more than 100 label claims for new drug and biologic approvals from FDA. Those label additions include potential drug-drug interactions (DDIs), formulation recommendations, dosing regimens, and data about new populations.

M&S is also increasingly being included in Japanese new drug applications (NDAs). PMDA announced in June that between 2014 and 2016, physiologically-based pharmacokinetic (PBPK) M&S reports were included in 17 NDAs.1 In those instances, M&S was used primarily to evaluate DDIs, predict drug exposure in pediatric patients and determine the impact of ethnic differences and disease states on drug PK.

The Simcyp Consortium was formed in 2001 to serve as a collaborative research center for PBPK and mechanistic modeling. Simcyp is now considered a global authority on PBPK and mechanistic M&S sciences, and the Simcyp Simulator has become the most sophisticated platform for predicting PK outcomes in virtual patient populations.

Simcyp Simulator data are used to inform a wide range of important management decisions, including formulation and clinical trial design, and the need for specific clinical trials, in addition to determining dosing in special populations and predicting the likelihood of DDIs. They can also identify preclinical data requirements, helping to refine early drug development processes and procedures.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing